Suggested remit: To appraise the clinical and cost effectiveness of lurbinectedin with atezolizumab within its marketing authorisation for maintenance treatment of extensive-stage small-cell lung cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6526
Provisional Schedule
- Committee meeting:
- 05 August 2026
- Expected publication:
- 02 December 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Immedica Pharma (lurbinectedin)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Asthma and Lung UK
- Black Health Agency for Equality
- Cancer Black Care
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Oncogene Cancer Research
- Roy Castle Lung Cancer Foundation
- Ruth Strauss Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- UK Lung Cancer Coalition
- Professional groups
- Association of Anaesthetists
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- Association of Surgeons of Great Britain and Ireland
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society of Interventional Radiology
- British Thoracic Oncology Group
- British Thoracic Society
- British Transplantation Society
- Cancer Research UK
- Lung Cancer and Mesothelioma Clinical Expert Group
- Lung Cancer Nursing UK
- National Heart and Lung Institute
- NHS Blood and Transplant
- Primary Care Respiratory Society
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Roche Products (atezolizumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Lung Cancer Group
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 January 2026 | Invitation to participate |
| 22 May 2025 - 20 June 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6526 |
| 22 May 2025 | In progress. Scoping commenced |
| 16 April 2025 | Referral |
| 30 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual